Synthetic options towards the manufacture of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl} - 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one

US12378246B2 · kind B2 · utility

Assignees

• Bristol-Myers Squibb Company · US
• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Nicolas Cuniere · Montgomery, US
• Yu Fan · Taipei, TW
• Sergei Kolotuchin · Princeton, US
• Subha MUKHERJEE · Princeton, US
• Eric M. Simmons · Princeton, US
• Amarjit SINGH · Princeton, US
• Carolyn S. Wei · Hoboken, US
• Yi Xiao · Fanwood, US
• Changxia Yuan · Pequest, US
• Bin Zheng · Kendall Park, US
• Simon Albert Wagschal · Schaffhausen, CH
• Diego Broggini · Schaffhausen, CH
• Duy Chi Trung CAO · Schaffhausen, CH
• Kostiantyn CHERNICHENKO · Beerse, BE
• Sebastien Francois Emmanuel Lemaire · Brussels, BE
• Cyril Ben Haim · Vosselaar, BE

Key dates

• Filing date: Apr 10, 2020
• Grant date: Aug 5, 2025
• Expiry date: Oct 18, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Highly efficient methods are provided for preparing key intermediates in the synthesis of Compound (I), which are broadly applicable and can provide selected components having a variety of substituents groups.